Related Experiment Video

Updated: Feb 25, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.2K

Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults

Rawad Elias1,2, Joshua Morales3, Carolyn Presley4,5

  • 1Section of Hematology Oncology, Boston University School of Medicine, Boston, MA, USA. raelias@bu.edu.

Current Oncology Reports
|July 30, 2017
PubMed

Insights

Older adults with non-small cell lung cancer (NSCLC) can benefit from immune checkpoint inhibitors (ICIs). This review examines ICI efficacy, safety, and challenges in this population.

Area of Science:

  • Oncology
  • Immunology
  • Geriatrics

Background:

  • Non-small cell lung cancer (NSCLC) predominantly affects older adults, with incidence and mortality rising sharply after age 65.
  • Immune checkpoint inhibitors (ICIs) represent a significant advancement in NSCLC treatment, shifting from traditional regimens.
  • Limited data exists on ICI effectiveness and safety specifically in elderly NSCLC patients, who often have complex health conditions.

Purpose of the Study:

  • To review the mechanism of action of ICIs in the context of NSCLC.
  • To analyze clinical trial data concerning ICI use in older adult populations.
  • To discuss potential challenges, including immune aging and toxicity, associated with ICIs in elderly NSCLC patients.

Main Methods:

  • Literature review of published clinical trials.
  • Analysis of data focusing on older adult cohorts within NSCLC trials.
  • Synthesis of information on ICI mechanisms, efficacy, and safety profiles.

Main Results:

  • ICIs have demonstrated efficacy in NSCLC treatment across various age groups.
  • Specific data on older adults (≥65 years) indicates potential benefits but also highlights unique considerations.
  • Immune aging and increased susceptibility to treatment-related toxicities are key factors in this demographic.

Conclusions:

  • Understanding the impact of ICIs in older adults with NSCLC is crucial for optimizing treatment strategies.
  • Further research is needed to define the specific benefits and risks of ICIs in the geriatric NSCLC population.
  • Addressing challenges like immune aging and toxicity is essential for safe and effective ICI utilization in elderly patients.
Keywords:
Immune agingImmune checkpoint inhibitorsNon-small cell lung cancerOlder adults

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
267
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
278
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
283
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
298